Acetaminophen News and Research

RSS

The pain-reliever acetaminophen (also known as paracetomol) is one of the best-selling over-the-counter medications, used by more than 200 million Americans a year. It is sold under many brand names, including Tylenol, and is an ingredient in nearly 200 medications, both over-the-counter (such as Excedrin, Midol, NyQuil, and Sudafed) and prescription (such as Vicodin).

Liver injury caused by herbals and dietary supplements increases 20% in U.S. study group

New research shows that liver injury caused by herbals and dietary supplements increased from 7% to 20% in a U.S. study group over a ten-year period.

4 Sep 2014

Review of clinical trials based on administering antidepressants for chronic postsurgical pain

After a systematic review of clinical trials based on administering antidepressants for acute and chronic postsurgical pain, researchers have concluded that more trials are needed to determine whether these drugs should be prescribed for postsurgical pain on a regular basis.

30 Aug 2014

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities.

15 Jul 2014

Mitek Sports Medicine expands early intervention options for sports medicine physicians and patients

Mitek Sports Medicine, a leader in orthopaedics sports medicine and a part of the DePuy Synthes Companies of Johnson & Johnson, announced the launch of MONOVISC High Molecular Weight Hyaluronan, a single-injection treatment for knee pain related to osteoarthritis and the PEAK Platelet Rich Plasma (PRP) System, a new device that produces high quality PRP in only 2.5 minutes.

14 Jul 2014

Pain control in osteoarthritis patients

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.

9 Jul 2014

Wake Forest Baptist Physician offers tips to prevent bites and rashes in summer

When summer rolls around, nothing beats soaking up the rays, hiking in a forest or playing Frisbee with the family … until a mosquito, bee or poisonous plant ruins the fun.

28 Jun 2014

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.

12 Jun 2014

Cumberland launches new Vaprisol product

Cumberland Pharmaceuticals Inc. today announced the launch of its active promotional campaign to support its new Vaprisol® product.

7 May 2014

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237).

30 Apr 2014

Enhanced recovery approach used for colorectal surgery cut hospital stays

Changes in managing patients before, during and after colorectal surgery cut hospital stays by two days and reduced readmission rates, according to researchers who led a study of the approach at Duke University Hospital.

25 Apr 2014

Anika Therapeutics reports first commercial sale of Monovisc in the U.S.

Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair, based on hyaluronic acid ("HA") technology, today announced the first U.S. commercial sale of Monovisc by its commercial partner, DePuy Synthes Mitek Sports Medicine, a leading orthopedic sports medicine company.

16 Apr 2014

New approach to breast reconstruction surgery decreases use of postoperative opioid painkiller

A new approach to breast reconstruction surgery aimed at helping patients' bodies get back to normal more quickly cut their postoperative opioid painkiller use in half and meant a day less in the hospital on average, a Mayo Clinic study found.

4 Mar 2014

ASN to conduct Scientific Sessions and Annual Meeting at Experimental Biology in San Diego

The American Society for Nutrition (ASN) will hold its 2014 Scientific Sessions and Annual Meeting at Experimental Biology (EB), from April 26-30, 2014, in San Diego. EB 2014 brings together the leading researchers from dozens of life-science disciplines.

3 Mar 2014

Study raises concerns about use of acetaminophen during pregnancy

Acetaminophen, found in over-the-counter products such as Excedrin and Tylenol, provides many people with relief from headaches and sore muscles. When used appropriately, it is considered mostly harmless. Over recent decades, the drug, which has been marketed since the 1950s, has become the medication most commonly used by pregnant women for fevers and pain.

27 Feb 2014

Anika Therapeutics receives marketing approval from FDA for MONOVISC injection

Anika Therapeutics, Inc. today announced it has received marketing approval for MONOVISC from the U.S. Food and Drug Administration. MONOVISC is a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients suffering from osteoarthritis (OA) of the knee.

26 Feb 2014

Children of women who used acetaminophen during pregnancy appear to be at higher risk for ADHD

Children of women who used the pain reliever acetaminophen (paracetamol) during pregnancy appear to be at higher risk for attention-deficit/hyperactivity disorder (ADHD)-like behavioral problems and hyperkinetic disorders.

26 Feb 2014

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.

11 Feb 2014

Study: Women who take aspirin daily may reduce risk of ovarian cancer by 20%

Women who take aspirin daily may reduce their risk of ovarian cancer by 20 percent, according to a study by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health. However, further research is needed before clinical recommendations can be made.

7 Feb 2014

Researchers identify key step to prevent liver failure resulting from painkiller overdose

University of Adelaide researchers have identified a key step for the future prevention of liver failure resulting from taking too much of the everyday painkiller paracetamol (also known as acetaminophen).

5 Feb 2014

Use of fever-reducing drugs may lead to tens of thousands more influenza cases

Contrary to popular belief, fever-reducing medication may inadvertently cause more harm than good. New research from McMaster University has discovered that the widespread use of medications that contain fever-reducing drugs may lead to tens of thousands more influenza cases, and more than a thousand deaths attributable to influenza, each year across North America.

22 Jan 2014